CNMD - コンメド （CONMED Corporation）

NEWARK, DE / ACCESSWIRE / May 25, 2023 / As per Future Market Insights'' latest industry analysis, the valuation for the USA knotless surgical sutures market was around US$ 175.7 Million in 2022 and is projected to exhibit a CAGR growth of close to 3.6% over the forecast period, with an estimated valuation of US$ 258.7 Million in 2033. Over the years, the USA market for knotless surgical sutures has seen tremendous growth. Key factors driving the market include technological advancements in terms of the usage of synthetic materials in creating surgical sutures, the development of absorbable sutures, increasing export opportunities, and rising disposable income. For insights on global, regional, and country-level parameters with growth opportunities from 2023 to 2033 - Download a sample @ https://www.futuremarketinsights.com/reports/sample/rep-gb-17299 Leading companies are inclined towards extensive research in order to develop new and improved versions of knotless surgical sutures. These include sutures with synthetic materials to provide exceptional tissue holding properties, sutures with properties like antibacterial or Triclosan-coated polyglactin 910 coated sutures, barbed sutures, sutures with braiding technologies, or absorbable sutures made of fibresthat line animal intestines or artificially created polymers.

https://www.investing.com/news/pro/conmed-corp-receives-investment-bank-analyst-rating-update-3087737

Conmed has performed as expected, with the stock price nearing the previously set target of $142. Read why CNMD should be on your watchlist.

Brinker Capital Investments LLC reduced its stake in shares of CONMED Co. (NYSE:CNMD – Get Rating) by 13.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,983 shares of the company’s stock after selling 1,250 shares during […]

Peter K Shagory , EVP at Conmed (NYSE: CNMD ), reported a large insider sell on May 2, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Tuesday showed that Shagory sold 2,442 shares of Conmed . The total transaction amounted to $312,576. Conmed shares are trading down 0.03% at $124.84 at the time of this writing on Wednesday morning. Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm. The Importance of Insider Transactions Insider transactions shouldn''t be used primarily to make an … Full story available on Benzinga.com

NEWARK, DE / ACCESSWIRE / May 25, 2023 / As per Future Market Insights'' latest industry analysis, the valuation for the USA knotless surgical sutures market was around US$ 175.7 Million in 2022 and is projected to exhibit a CAGR growth of close to 3.6% over the forecast period, with an estimated valuation of US$ 258.7 Million in 2033. Over the years, the USA market for knotless surgical sutures has seen tremendous growth. Key factors driving the market include technological advancements in terms of the usage of synthetic materials in creating surgical sutures, the development of absorbable sutures, increasing export opportunities, and rising disposable income. For insights on global, regional, and country-level parameters with growth opportunities from 2023 to 2033 - Download a sample @ https://www.futuremarketinsights.com/reports/sample/rep-gb-17299 Leading companies are inclined towards extensive research in order to develop new and improved versions of knotless surgical sutures. These include sutures with synthetic materials to provide exceptional tissue holding properties, sutures with properties like antibacterial or Triclosan-coated polyglactin 910 coated sutures, barbed sutures, sutures with braiding technologies, or absorbable sutures made of fibresthat line animal intestines or artificially created polymers.

https://www.investing.com/news/pro/conmed-corp-receives-investment-bank-analyst-rating-update-3087737

Conmed has performed as expected, with the stock price nearing the previously set target of $142. Read why CNMD should be on your watchlist.

Brinker Capital Investments LLC reduced its stake in shares of CONMED Co. (NYSE:CNMD – Get Rating) by 13.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,983 shares of the company’s stock after selling 1,250 shares during […]

Peter K Shagory , EVP at Conmed (NYSE: CNMD ), reported a large insider sell on May 2, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Tuesday showed that Shagory sold 2,442 shares of Conmed . The total transaction amounted to $312,576. Conmed shares are trading down 0.03% at $124.84 at the time of this writing on Wednesday morning. Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm. The Importance of Insider Transactions Insider transactions shouldn''t be used primarily to make an … Full story available on Benzinga.com

CONMED Corporation (NYSE: CNMD ) shares are trading higher after the company reported better-than-expected Q1 earnings . It reported Q1 adjusted EPS of $0.66, beating the consensus of $0.60 but down 5.7% Y/Y. The Q1 sales came in at $295.47 million, up 21.9% (25.1% in constant currency), surpassing the consensus of $266.67 million. The company raised FY23 revenue guidance to $1.205-$1.250 billion from $1.170-$1.220 billion expected earlier, versus the consensus of $1.19 billion. FY23 adjusted EPS is expected to be $3.30 to $3.50, compared to its prior range of $3.20-$3.45 and … Full story available on Benzinga.com

The following slide deck was published by CONMED Corporation in conjunction with their 2023 Q1 earnings call.

CONMED Corporation (NYSE:NYSE:CNMD) Q1 2023 Results Earnings Conference Call April 27, 2023 4:30 PM ETCompany ParticipantsCurt Hartman - Chair of the Board, President, and Chief Executive…

CONMED press release (CNMD): Q1 Non-GAAP EPS of $0.66 beats by $0.06.Revenue of $295.5M (+21.9% Y/Y) beats by $28.84M.Now expects FY 2023 revenue between $1.205 billion and…

NEWARK, DE / ACCESSWIRE / April 25, 2023 / The global Electrosurgery Generator Market is predicted to be worth US$ 1.6 Billion in 2023, and to grow at a CAGR of 7.7% to be worth US$ 3.4 Billion by the end of 2033. Changing the electrical current that the electrosurgical generating units (ESU) produce into heat energy within tissue is a process known as electrosurgery. The rise in surgical procedures is one of the key factors anticipated to propel the growth of the market for electrosurgical generators during the forecast period. Demand for minimally invasive procedures as well as the rising ageing population further adds to the growth of the market. The ability to cut or cauterize tissue with a high-frequency electrical current makes electrosurgical generators (ESG) more and more common. Because it provides surgeons with a precise and controllable energy source during surgery, an ESG is essential. With the help of this electrical energy, the tissue is cut or coagulated. Electrosurgery Generator demand is expected to rise due to the demand for least invasive procedures.